TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporn vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporn VTP treatment of patients with low-grade upper tract urothelial cancer (UTUC), will be presented at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC 2024) taking place November 7 – 10, 2024,in Lisbon, Portugal.
Poster & Session Details:
Poster Title: ENLIGHTED Phase 3 study: Efcacy and Safety of Padeliporn Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC)
Presenter: Gautier Marcq, M.D., M.Sc.
Poster Number: P225
Session Title: EMUC24 Networking and Abstract Discussion Session
Session Date & Time: November 9, 2024, 17:30 GM
About ImPact Biotech
ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporn Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non thermal laser light via optical bers to locally activate Padeliporn in the tumor microenvironment. Padeliporn VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com.